Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya

Vaccine

Volumn 37, Issue 17, 2019, Pages 2377-2386

  Lee, Bruce Y ^a,b   Brown, Shawn T ^c,d   Haidari, Leila A ^c   Clark, Samantha ^e   Abimbola, Taiwo ^f   Pallas, Sarah E ^f   Wallace, Aaron S ^f   Mitgang, Elizabeth A ^a,b   Leonard, Jim ^c   Bartsch, Sarah M ^a,b   Yemeke, Tatenda T ^g   Zenkov, Eli ^c   Ozawa, Sachiko ^g,h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNC Hamner Institute for Drug Safety Sciences   (United States)

^h University of North Carolina at Chapel Hill   (United States)

Author keywords

Economic; Hard to reach populations; Vaccination

Indexed keywords

MEASLES VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY-ADJUSTED LIFE YEAR; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SURVEY; IMMUNOLOGY; MEDICAL GEOGRAPHY; PROCEDURES; RISK FACTOR; THEORETICAL MODEL; VACCINATION;

COST-BENEFIT ANALYSIS; GEOGRAPHY, MEDICAL; HUMANS; KENYA; MEASLES; MEASLES VACCINE; MODELS, THEORETICAL; POPULATION SURVEILLANCE; RISK FACTORS; VACCINATION;

EID: 85063294118     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2019.03.007     Document Type: Article

References (47)

1. World Health Organization. Global measles and rubella strategic plan: 2012; 2012.
2. Organization, W.H. and UNICEF. Increasing immunization coverage at the health facility level. Geneva: World Health Organization; 2002.
3. Feldstein, L.R., et al. Global routine vaccination coverage, 2016, in Morbidity and Mortality Weekly Report (MMWR). 2017, Centers for Disease Control and Prevention, Atlanta.
4. VanderEnde, K., et al. Global routine vaccination coverage — 2017, in Morbidity and Mortality Weekly Report (MMWR). 2018, Centers for Disease Control and Prevention, Atlanta.
5. Kisangau, N., et al. Progress towards elimination of measles in Kenya, 2003–2016. Pan Afr Med J, 31(65), 2018.
6. Vijayaraghavan, M., et al. Measles supplemental immunization activities improve measles vaccine coverage and equity: Evidence from Kenya, 2002. Health Policy 83:1 (2007), 27–36.
7. World Health Organization. The RED Strategy. Available from: http://www.who.int/immunization/programmes_systems/service_delivery/red/en/; 2016.
8. Vandelaer, J., Bilous, J., Nshimirimana, D., Reaching Every District (RED) approach: a way to improve immunization performance. Bull World Health Organ, 86(3), 2008 p. A-b.
9. Ryman, T., et al. Reaching every district (RED) approach to strengthen routine immunization services: evaluation in the African region, 2005. J Public Health (Oxf) 32:1 (2010), 18–25.
10. Instituto Nacional de Estatística Moçambique. 2015 [cited 2015 April]; Available from: http://www.ine.gov.mz/.
11. World Bank. The 2013 World Bank Development Indicators. Washington, DC: World Bank; 2014.
12. WHO. Immunization schedules by antigens. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules; 2016.
13. WHO and UNICEF. WHO/UNICEF estimates of national immunization coverage (WUENIC). Available from: 2015.
14. Haidari, L.A., et al. The economic value of increasing geospatial access to tetanus toxoid immunization in Mozambique. Vaccine 34:35 (2016), 4161–4165.
15. CIESIN, FAO, and CIAT. Global Rural-Urban Mapping Project, Version 1 (GRUMPv1): Population count grid. Palisades, NY: NASA Socioeconomic Data and Applications Center (SEDAC); 2000.
16. World Bank. GNI per capita, Atlas method; 2015.
17. Toikilik, S., et al. Are hard-to-reach populations being reached with immunization services? Findings from the 2005 Papua New Guinea national immunization coverage survey. Vaccine 28:29 (2010), 4673–4679.
18. Rainey, J.J., et al. Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999–2009. Vaccine 29:46 (2011), 8215–8221.
19. WHO. Immunization in practice: a practical guide for health staff, 2015 update. Available from: http://apps.who.int/iris/bitstream/10665/193412/1/9789241549097_eng.pdf.
20. van Hoek, A.J., et al. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS ONE, 7(10), 2012, e47511.
21. Antillón, M., et al. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings. Vaccine 35:27 (2017), 3506–3514.
22. Woods, B., et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value in Health 19:8 (2016), 929–935.
23. Bertram, M.Y., et al. Cost–effectiveness thresholds: pros and cons. Bull World Health Organ, 94(12), 2016, 925.
24. Global Vaccine Action Plan 2011-2020. Available from: http://who.int/iris/bitstream/10665/78141/1/9789241504980_eng.pdf; 2013.
25. Gavi, the Vaccine Alliance, 2016-2020 Strategy. Geneva: Gavi, the Vaccine Alliance; 2014.
26. Ozawa, S., Yemeke, T.T., Thompson, K.M., Systematic review of the incremental costs of interventions that increase immunization coverage. Vaccine 36:25 (2018), 3641–3649.
27. National and County Health Budget Analysis FY 2016/17. Nairobi: Kenya Ministry of Health; 2017.
28. Van Malderen, C., et al. Decomposing Kenyan socio-economic inequalities in skilled birth attendance and measles immunization. Int J Equity Health, 12, 2013, 3.
29. Ferrari, M.J., et al. The dynamics of measles in sub-Saharan Africa. Nature 451:7179 (2008), 679–684.
30. Thompson, K.M., Odahowski, C.L., The costs and valuation of health impacts of measles and rubella risk management policies. Risk Anal 36:7 (2016), 1357–1382.
31. WHO-CHOICE Country specific unit costs. [cited 2016 25 Feb]; Available from: http://www.who.int/choice/costs/en/; 2008.
32. US State Department. Country Reports on Human Rights Practices for 2012. Available from: http://www.state.gov/j/drl/rls/hrrpt/humanrightsreport/index.htm; 2014.
33. Kim, S.Y., et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health, 10, 2010, 253.
34. WHO. Global Health Observatory Life tables. Available from: http://www.who.int/gho/mortality_burden_disease/life_tables/life_tables/en/; 2012.
35. World Bank. World Development Indicators, Kenya. Available from: http://data.worldbank.org/country/kenya.
36. United Nations. Department of Economic and Social Affairs, Population Division, in World Population Prospects: The 2015 Revision, DVD Edition; 2015.
37. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention, Atlanta, GA, 2008.
38. Salomon, J.A., et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3:11 (2015), e712–e723.
39. Cost-effectiveness in health and medicine. In: Gold M, et al., editor. New York, NY: Oxford University Press; 1996.
40. Wolfson, L.J., et al. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol 38:1 (2009), 192–205.
41. UNICEF. Vaccine price data. Available from: http://www.unicef.org/supply/index_57476.html; 2016.
42. Republic of Kenya Ministry of Health Division of Vaccines and Immunization. Kenya comprehensive multi-year plan 2011-2015; 2011.
43. World Health Organization. WHO prequalified vaccines; April 2016.
44. WHO. Global reference list of 100 core health indicators. Available from: http://www.who.int/healthinfo/indicators/2015/en/; 2015.
45. Webber, R., Communicable diseases: a global perspective. 4th ed., 2012, CABI, Cambridge, MA.
46. Anderson, R., May, R., Infectious disease of humans. 1991, Oxford University Press, Oxford.
47. Uzicanin, A., Zimmerman, L., Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 204:Suppl 1 (2011), S133–S148.